Kalaris Therapeutics(KLRS)
$1.43-0.03 (-2.05%)
KLRS
Kalaris Therapeutics financials statements
$1.43
At close:-0.03 (-2.05%)
Want to see KLRS full AI Analyst Report?
Kalaris Therapeutics (KLRS) Ratios
399 Followers
Kalaris Therapeutics Ratios
KLRS's free cash flow for Q3 2026 was $-10.55M. For the 2026 fiscal year, KLRS's free cash flow was increased by $0.00 and operating cash flow was $-10.55M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.23 | 22.63 | 0.85 | 0.69 | 6.69 |
| Quick Ratio | 12.23 | 22.63 | 0.85 | 0.69 | 6.69 |
| Cash Ratio | 10.09 | 22.58 | 0.80 | 0.54 | 5.33 |
| Solvency Ratio | -1.01 | -11.22 | -0.30 | -0.45 | -2.79 |
| Operating Cash Flow Ratio | -3.95 | -12.92 | -3.58 | -1.72 | -2.81 |
| Short-Term Operating Cash Flow Coverage | -121.42 | 0.00 | 0.00 | 0.00 | -16.13 |
| Net Current Asset Value | $ 75.89M | $ 113.31M | $ -45.02M | $ -30.27M | $ 192.02M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.83 | 0.10 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | 0.00 | -0.11 | 0.13 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | -0.12 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -0.12 | 0.00 |
| Financial Leverage Ratio | 1.54 | 1.05 | -0.07 | -0.13 | 1.27 |
| Debt Service Coverage Ratio | -23.87 | 0.00 | -20.40 | -64.89 | -25.92 |
| Interest Coverage Ratio | -31.98 | 0.00 | -19.60 | -59.60 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.11 | 0.26 |
| Interest Debt Per Share | 0.19 | 0.00 | 0.15 | 1.05 | 11.01 |
| Net Debt to EBITDA | 2.30 | 2.01 | 0.23 | -0.01 | 1.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.59% |
| EBT Per EBIT | 94.12% | 106.36% | 109.17% | 110.56% | 100.67% |
| Return on Assets (ROA) | -35.68% | -49.57% | -441.01% | -397.15% | -60.00% |
| Return on Equity (ROE) | -55.11% | -51.87% | 32.65% | 51.15% | -76.34% |
| Return on Capital Employed (ROCE) | -41.20% | -48.77% | 2210.84% | 781.58% | -68.27% |
| Return on Invested Capital (ROIC) | -41.08% | -48.77% | 2210.84% | 781.58% | -66.51% |
| Return on Tangible Assets | -35.68% | -49.57% | -441.01% | -397.15% | -60.00% |
| Earnings Yield | -33.71% | -5.28% | -35.62% | -50.95% | -690.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.13 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -35966.54 | 0.00 | 0.00 | 0.00 | -2732.11 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 35966.54 | 0.00 | 0.00 | 0.00 | 2732.11 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.51 | -13.52 | -3.12 | -2.93 | -38.95 |
| Free Cash Flow Per Share | -2.53 | -13.52 | -3.12 | -2.93 | -38.96 |
| Dividend Paid and CapEx Coverage Ratio | -191.85 | 0.00 | 0.00 | 0.00 | -4089.19 |
| Capital Expenditure Coverage Ratio | -191.85 | 0.00 | 0.00 | 0.00 | -4089.19 |
| Operating Cash Flow Coverage Ratio | -26.50 | 0.00 | 0.00 | -3.01 | -3.54 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -29.93% | -6.08% | -34.25% | -32.17% | -427.18% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.96 | -18.94 | -2.81 | -1.96 | -0.14 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.63 | 9.82 | -0.92 | -1.00 | 0.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.34 | -16.44 | -2.92 | -3.11 | -0.23 |
| Price-to-Operating Cash Flow Ratio | -3.36 | -16.44 | -2.92 | -3.11 | -0.23 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.26 | 0.17 | 0.10 | -0.03 |
| Enterprise Value Multiple | -0.77 | -16.92 | -2.72 | -2.01 | 0.86 |
| Enterprise Value | 32.25M | 994.49M | 38.09M | 30.59M | -146.70M |
| EV to EBITDA | -0.77 | -16.92 | -2.72 | -2.01 | 0.86 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.84 | -14.69 | -2.70 | -3.13 | 1.38 |
| EV to Operating Cash Flow | -0.84 | -14.69 | -2.70 | -3.13 | 1.38 |
| Tangible Book Value Per Share | 5.16 | 22.62 | -9.95 | -9.08 | 82.53 |
| Shareholders’ Equity Per Share | 5.16 | 22.62 | -9.95 | -9.08 | 82.53 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.85 | -11.73 | -3.25 | -4.65 | -63.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Interest Burden | 1.03 | 1.00 | 1.05 | 1.02 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.88 | 1.15 | 0.96 | 0.63 | 0.62 |
Currency in USD

